FDA risks falling short on performance goals
This article was originally published in Clinica
Executive Summary
The FDA must undergo "significant improvement" in its review performance in certain areas in order to meet its performance goals pledged in exchange for user fees, the agency notes in its first quarter fiscal year 2004 report.